Larger Therapeutic Window for Steroid versus VEGF-A Inhibitor in Inflammatory Angiogenesis: Surprisingly Similar Impact on Leukocyte Infiltration | Zendy

Shintaro Nakao | Zendy; Souska Zandi | Zendy; Nuria Lara-Castillo | Zendy; Mahdi Taher | Zendy; Tatsuro Ishibashi | Zendy; Ali HafeziMoghadam | Zendy

Open Access

Larger Therapeutic Window for Steroid versus VEGF-A Inhibitor in Inflammatory Angiogenesis: Surprisingly Similar Impact on Leukocyte Infiltration

Author(s) -

Shintaro Nakao,

Souska Zandi,

Nuria Lara-Castillo,

Mahdi Taher,

Tatsuro Ishibashi,

Ali HafeziMoghadam

Publication year - 2012

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.11-8114

Subject(s) - bevacizumab , angiogenesis , dexamethasone , medicine , vascular endothelial growth factor , cancer research , neovascularization , pharmacology , endocrinology , chemotherapy , vegf receptors

The current treatments against inflammatory angiogenesis are steroids and anti-VEGF-A, such as dexamethasone and bevacizumab, respectively. However, the therapeutic windows for dexamethasone and bevacizumab against inflammatory angiogenesis are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research